摘要
目的比较不同剂量的聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的效果及安全性。方法选取2009年3月～2010年4月在广西医科大学第一附属医院感染病科治疗慢性丙肝的26例患者作为研究对象,随机分为低剂量组与高剂量组,两组患者各13例,分别肌注聚乙二醇干扰素α-2b注射液1.0、1.5μg/kg,每周1次,口服利巴韦林胶囊均为1000 mg/d。疗程为24周。每周进行谷丙转氨酶(ALT)水平和丙型肝炎正链RNA病毒(HCV-RNA)载量检测及28项生化检查,计算应答率并观察其不良反应发生情况,数据采用统计学软件SPSS16.0进行分析。结果两组剂量对治疗慢性丙肝的疗效相近,其中高低剂量组的完全应答率分别为53.85%(7/13)和46.15%(6/13),部分应答率分别为23.08%(3/13)和30.77%(4/13),应答率均为76.92%,三者间数据差异均无统计学意义(P>0.05);两组患者的不良反应发生率相近,程度总体较轻,但高剂量组的头痛和发热发生率明显高于低剂量组,差异有统计学意义(P<0.05)。结论高低剂量的聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎均能达到理想效果,且不良反应较轻,二者无显著差异,但考虑到长期用药的安全性和经济性,低剂量组具有一定优势,值得临床上进一步推广。
Objective To compare the effect and safety degree of Pegylated Interferon α-2b in combination with Ribovirin in different doses on the chronic hepatitis C therapy.Methods 26 patients of chronic hepatitis C in the Affiliated Hospital of Guangxi Medical University from March 2009 to April 2010 were taken as subjects and randomly di vided into a low-dose group a high-dose group of 13 cases respectively,with 1.0,1.5 μg/kg administration accordingly once a week,with patients taking in 1000 mg Ribavirin per day,the study period was 24 weeks.The ALT and HCVRNA viral capacity and 28 biochemical tests were checked every week,with the response rate calculated and the ad verse reactions observed.Then the result was analyzed via SPSS 16.0.Results The two different doses had similar effect on the chronic hepatitis C.therapy.The total response rates of high-dose group and lose-dose group were 53.85%（7/13） and 46.15%（6/13） respectively.And the corresponding partial response rates were 23.08%（3/13） and 30.77%（4/13）,and the corresponding response rates were 76.92%.There was no statistical sense in the differentiation among them（P〈0.05）;the adverse reaction rates between the two groups were similar,but not very high.However,the inci dence of headache and fever occurred more in the high-dose group,which was of great statistical significance（P〈0.05）.Conclusion Pegylated Interferon α-2b in combination with Ribovirin in both doses may result in ideal therapy effects and low adverse reaction rate.There is no big difference.In view of long-term safety and principle of economy,the low-dose therapy is of comparable advantage and deserves further clinical application.
出处
《中国医药导报》
CAS
2013年第24期92-94,共3页
China Medical Herald
基金
广东省东莞市高等院校科研机构和医疗卫生单位科技计划项目(编号2008105150008)
